Chemistry:Elecoglipron

From HandWiki

Elecoglipron is an investigational new drug that is being developed by Eccogene and AstraZeneca for the treatment of obesity, type 2 diabetes mellitus, and liver disorders. It is a glucagon-like peptide-1 receptor agonist. [1][2][3]

References

  1. ↑ "Elecoglipron". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800070790. 
  2. ↑ "Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial". Lancet (London, England) 407 (10547): 2515–2527. June 2026. doi:10.1016/S0140-6736(26)00802-0. PMID 42259343. 
  3. ↑ "Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial". Lancet (London, England) 407 (10547): 2503–2514. June 2026. doi:10.1016/S0140-6736(26)00748-8. PMID 42259337. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Elecoglipron&oldid=4645222"